<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128137</url>
  </required_header>
  <id_info>
    <org_study_id>2018-003905-25</org_study_id>
    <nct_id>NCT04128137</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension</brief_title>
  <official_title>Evaluation of Efficacy and Tolerance of Fludrocortisone (Flucortac) in the Treatment of Orthostatic Neurogenic Hypotension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H.A.C. PHARMA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H.A.C. PHARMA</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of a 4-week fludrocortisone (FLU) treatment on systolic blood
      pressure depression after 5 minutes of active orthostatism in patients with neurogenic
      orthostatic hypotension (HON) symptomatic, despite treatment with non-drug measures with or
      without midodrine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to demonstrate the efficacy of FLU on systolic blood pressure
      depression in patients with neurogenic orthostatic hypotension. The study is randomised
      versus placebo.Each patient will be followed for a maximum of 5 months, with no more than 8
      visits to the investigator (V0 at Day-7, V1 at D0, V2 at D7, V3 at D+14, V4 at D+21, V5 at D+
      28, V6 at D+56 and V7 only for patients on the FLU arm at D+140.

      The presence of a comparator control group with placebo permits to evaluate the efficacy and
      the tolerance of FLU independently of the natural evolution of the pathology, in patients
      benefiting from a non-drug or possibly medicated treatment (midodrine) but insufficient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic BP diminution</measure>
    <time_frame>8 weeks</time_frame>
    <description>Systolic BP diminution when moving from supine to standing, measured with a semi-automatic blood pressure monitor
- AP in upright position: the lowest value of the measurements obtained every minute, for 5 minutes after rising.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Neurogenic Orthostatic Hypotension</condition>
  <arm_group>
    <arm_group_label>fludrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FLUCORTAC® 50 μg (tablet breackable). One tablet during the first week. Then 2 tablets during the second week. Then 3 tablets during the third week and finally 4 tablets during the 4th week. Maximum of 200μg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo of flucortac and same diagram of administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludrocortisone</intervention_name>
    <description>50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose</description>
    <arm_group_label>fludrocortisone</arm_group_label>
    <other_name>Flucortac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of orthostatic hypotension (HO), ie a blood pressure drop&gt; 20 and / or 10
             mmHg within 3 minutes after active and symptomatic lifting

          -  Patient suffering from a neurological disease

          -  orthostatic neurogenic hypotension persistent and symptomatic despite non-drug
             measures

        Exclusion Criteria:

          -  Hypersensitivity to FLU or any of its excipients

          -  non orthostatic neurogenic hypotension

          -  History of proven heart failure

          -  History of left ventricular systolic dysfunction

          -  Uncompensated hypokalemia

          -  Patient with poorly balanced Grade 3 hypertension

          -  Pregnant patient at the time of inclusion

          -  Nursing patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Michel SENARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Coordinator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine DENICOURT</last_name>
    <phone>02 31 47 92 46</phone>
    <email>catherine.denicourt@hacpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Broca (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier HANON, MD</last_name>
      <email>Olivier.hanon@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

